Antipsychotic drug efficacy may have decreased over recent decades. The authors present a meta-analysis of all placebo-controlled trials in patients with acute exacerbations of schizophrenia, and they investigate which trial characteristics have changed over the years and which are moderators of drug-placebo efficacy differences. Login at top right hand side of page using your SSSFT NHS Athens for full text. SSOTP - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
While psychotic experiences (PEs) are known to be associated with a range of mental and general medical disorders, little is known about the association between PEs and measures of disability. We aimed to investigate this question using the World Mental Health surveys. Login using your SSSFT NHS OpenAthens for full text. SSOTP - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Mesolimbic dopamine sensitization has been hypothesized to be a mediating factor of childhood adversity (CA) on schizophrenia risk. Activity of catechol-O-methyltransferase (COMT) Val158Met increases mesolimbic dopamine signaling and may be further regulated by methylenetetrahydrofolate reductase (MTHFR) C677T. This study investigates the three-way interaction between CA, COMT, and MTHFR. Login using your SSSFT NHS OpenAthens for full text. SSOTP - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Editorial. Login using your SSSFT NHS OpenAthens for full text. SSOTP - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
People with serious mental illness (SMI) are at risk of dying many years earlier than the general population. Providing an effective, cost-efficient healthcare service requires a holistic approach, and improving the physical health of people with SMI should be integral to all healthcare roles. It is important for nurses to identify and understand the barriers that people with SMI may experience when accessing physical healthcare.
To read the full article, log in using your NHS OpenAthens details
Raphael Underwood on a systematic review of stigma and pathways to care for people at risk of psychotic disorders or experiencing first-episode psychosis.
One of the greatest challenges for the identification of the causes and cures for schizophrenia is the overwhelming heterogeneity of the disorder. Schizophrenia is defined by symptoms that have only weak associations with one another and are found in patients with other illnesses. Further, some of the most devastating symptoms, such as cognitive impairment and amotivation, are present in segments of the healthy general population. Our inability to define sharp boundaries in the clinical presentation of the illness has hampered research efforts to identify treatments. There are no single genes of substantial effect that can identify patients, no clear biological markers, and, despite decades of research on the structure and function of the brains of these patients, no neuroanatomical abnormality that clearly distinguishes a person with schizophrenia from someone who is healthy. The absence of clear boundaries among patients with severe mental illness has significant implications for treatment and treatment development. There are 23 antipsychotic medications approved for use in the United States, but there is precious little reliable information to determine which patients should receive which medication.1 And while our understanding of human neurobiology advances swiftly, if we have no biological means to separate those who will benefit from a treatment from those who will not, then clinical trials for new treatments will be challenged to succeed. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai